• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan’s Q3 misses on $465 million Medicaid settlement

November 10, 2016 By Sarah Faulkner

Mylan misses on top & bottom lines, citing $465 million settlementShares in Mylan (NDSQ:MYL) rose slightly today after the pharmaceutical giant missed expectations on Wall Street with its 3rd-quarter results.

The Canonsburg, Pa.-based company posted a net loss of -$119.8 million, or -23¢ per share, on sales of $3.06 billion for the 3 months ended Sept. 30, for a bottom-line slide of -3% on sales growth of 14.2% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.38, behind the $1.45 consensus on The Street, where analysts were looking for sales of $3.12 billion.

“Our 3rd-quarter results were consistent with the full-year guidance we provided a few weeks ago. During the quarter, we reported strong performance across our European and rest-of -world regions, as well as solid performance across our North American region despite challenging year-over-year comparisons due to the significant contribution from new products in last year’s 3rd quarter. In our specialty segment, while EpiPen auto-injector scripts grew quarter-over-quarter, volumes were down due to the lack of wholesaler purchases in the quarter in anticipation of our upcoming generic launch,” CEO Heather Bresch >said in prepared remarks. “Over the next 18 to 24 months, we will focus on integrating and driving efficiencies across our global platform and we will be considering how best to deploy our capital and leverage our differentiated platform over the longer term to ensure Mylan’s sustainable growth for many years to come.”

Mylan said it expects to post full-year adjusted EPS of $4.70 to $4.90, down from previous guidance of $4.85 to $5.15.

The company is working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment. Mylan told Reuters that the money set aside for the settlement ultimately led to the Q3 loss. The company reported in October that it would pay a $465 million settlement, but the U.S. government has not confirmed the agreement.

Mylan has been under fire since August, when reports surfaced that it had raised the price of its device by 500% over the past decade. Bresch has since testified before Congress about the company’s pricing strategies, but some politicians are calling on regulatory groups to investigate.

On a conference call with analysts, Bresch reportedly claimed that high deductible health plans and pricing pressures created headwinds for its business in the U.S. “We wish we had better anticipated the acceleration for rising out-of-pocket costs” for our customers, she said.

MYL shares were trading at $39.99 apiece today in morning trading, up 2.8%.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Respiratory, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS